Radiotherapy for non-small cell lung cancer: evolution and development

doi:10.19401/j.cnki.1007-3639.2020.10.008

Welcome to China Oncology,

China Oncology ›› 2020, Vol. 30 ›› Issue (10): 777-784.doi: 10.19401/j.cnki.1007-3639.2020.10.008

• Specialists’ Commentary and Article • Previous Articles Next Articles

Radiotherapy for non-small cell lung cancer: evolution and development

XU Xinyan ¹ , CHEN Jiayan ¹ , MAO Jingfang ^{1, 2} , FAN Min¹#br#

1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; 2. Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai 201321, China

Online:2020-10-30 Published:2020-11-12
Contact: FAN Min E-mail: fanming@fudan.edu.cn

Share article

Abstract

Abstract: Lung cancer is the leading cause of tumor-related death worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Radiotherapy has long been one of the fundamental therapeutic approaches for lung cancer. Over the years, with the ever-accelerated development of radiotherapy technology and the deepened basic and clinical research on NSCLC, the application of radiotherapy in lung cancer treatment has been dramatically expanded, with a promising landscape for future development.

Key words: Lung cancer, Radiotherapy, Progress

XU Xinyan , CHEN Jiayan , MAO Jingfang , FAN Min . Radiotherapy for non-small cell lung cancer: evolution and development[J]. China Oncology, 2020, 30(10): 777-784.

[1]	WANG Zhiqing, LIU Xiyu, FAN Lei. Advances and controversies in the adjuvant treatment of early breast cancer [J]. China Oncology, 2025, 35(3): 255-262.
[2]	LU Yongjin, SHI Zhiqiang, LI Tong, WANG Yongsheng, QIU Pengfei. Retrospective study on regional lymph node radiotherapy after axillary dissection exemption in breast cancer patients with sentinel lymph node positive status [J]. China Oncology, 2025, 35(2): 228-236.
[3]	WANG Manli, CHEN Hui, DUAN Zhi, XU Qimei, LI Zhen. A study on communication mechanism of lung cancer cells in tumor microenvironment mediated by pleckstrin-2/miR-196a signal axis [J]. China Oncology, 2024, 34(7): 628-638.
[4]	QIAN Bin, CHEN Haiquan. Important progress in surgical treatment of lung cancer in 2023 [J]. China Oncology, 2024, 34(4): 335-339.
[5]	FENG Zheng, GUO Qinhao, ZHU Jun, WU Xiaohua, WEN Hao. Progress in treatment of gynecological cancer in 2023 [J]. China Oncology, 2024, 34(4): 340-360.
[6]	LIN Yicong, WANG Yue, XUE Qianqian, ZHENG Qiang, JIN Yan, HUANG Ziling, LI Yuan. Clinical pathological characteristics and immune microenvironment significance of EGFR T790M mutation in non-small cell lung cancer patients and its prognostic implications [J]. China Oncology, 2024, 34(4): 368-379.
[7]	XU Yonghu, XU Dazhi. Progress and prospects of gastric cancer treatment in the 21st century [J]. China Oncology, 2024, 34(3): 239-249.
[8]	WANG Xuefei, ZHOU Peng, TANG Zhaoqing. New progress and development trend of surgical treatment for gastric cancer [J]. China Oncology, 2024, 34(3): 250-258.
[9]	JIANG Mengqi, HAN Yuchen, FU Xiaolong. Research progress on H-E stained whole slide image analysis by artificial intelligence in lung cancer [J]. China Oncology, 2024, 34(3): 306-315.
[10]	ZHANG Qi, XIU Bingqiu, WU Jiong. Progress of important clinical research of breast cancer in China in 2023 [J]. China Oncology, 2024, 34(2): 135-142.
[11]	ZHANG Siyuan, JIANG Zefei. Important research progress in clinical practice for advanced breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 143-150.
[12]	HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer [J]. China Oncology, 2024, 34(2): 185-190.
[13]	LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. China Oncology, 2024, 34(2): 191-200.
[14]	CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran. A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy [J]. China Oncology, 2024, 34(11): 1036-1044.
[15]	CUI Jianchun, LU Wei, LI Qianyong. Clinical application value of surface-guided automatic positioning in pelvic tumor radiotherapy [J]. China Oncology, 2024, 34(10): 966-971.

Radiotherapy for non-small cell lung cancer: evolution and development

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments